期刊
JOURNAL OF CONTROLLED RELEASE
卷 342, 期 -, 页码 241-279出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2022.01.008
关键词
RNA drugs; Non-viral vector; Biological barrier; Control release; Gene therapy
资金
- National Natural Science Foundation of China [81773650, 81690264, 81973259]
- Beijing Natural Science Foundation [J200018]
- National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology of China [2018ZX09721003-004]
RNA-based therapy is a promising strategy for disease treatment, and recent advances in non-viral delivery systems have shown potential in protecting RNA, facilitating cell internalization, and controlled release of therapeutics.
RNA-based therapy is a promising and potential strategy for disease treatment by introducing exogenous nucleic acids such as messenger RNA (mRNA), small interfering RNA (siRNA), microRNA (miRNA) or antisense oligonucleotides (ASO) to modulate gene expression in specific cells. It is exciting that mRNA encoding the spike protein of COVID-19 (coronavirus disease 2019) delivered by lipid nanoparticles (LNPs) exhibits the efficient protection of lungs infection against the virus. In this review, we introduce the biological barriers to RNA delivery in vivo and discuss recent advances in non-viral delivery systems, such as lipid-based nanoparticles, polymeric nanoparticles, N-acetylgalactosamine (GalNAc)-siRNA conjugate, and biomimetic nanovectors, which can protect RNAs against degradation by ribonucleases, accumulate in specific tissue, facilitate cell internalization, and allow for the controlled release of the encapsulated therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据